Status:
COMPLETED
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Loma Linda University
Conditions:
Secondary Hyperparathyroidism
Eligibility:
All Genders
6-21 years
Phase:
NA
Brief Summary
FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of...
Eligibility Criteria
Inclusion
- Inclusion criteria include pediatric patients, between the ages of 2 and 21 years, with CKD stages 2-4 (GFR 15-90 ml/min/1.73m2).
Exclusion
- Exclusion criteria include: the use of phosphate binder therapy within the past 3 months, treatment with 25(OH)vitamin D or 1,25dihydroxyvitamin D, underlying metabolic bone disease, or underlying renal phosphate wasting disorder.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00999037
Start Date
October 1 2009
End Date
June 1 2015
Last Update
May 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90095